Receive our newsletter – data, insights and analysis delivered to you
July 19, 2009

Swine Flu Virus Provides Slim Pickings for Vaccine, says Novartis

A spokesperson for Novartis AG has revealed the difficulty of producing a vaccine against the H1N1 flu pandemic because the virus yields very little of the antigen needed. According to Bloomberg.com, Novartis spokesperson Eric Althoff revealed that lab workers are harvesting one do

By cms admin

A spokesperson for Novartis AG has revealed the difficulty of producing a vaccine against the H1N1 flu pandemic because the virus yields very little of the antigen needed.

According to Bloomberg.com, Novartis spokesperson Eric Althoff revealed that lab workers are harvesting one dose or less of the component they need from each egg in which the virus is grown, around half or a third of what it takes to provide a typical seasonal flu vaccine.

Most flu vaccines are produced by injecting chicken eggs with an approved version of the virus. The virus is then allowed to grow rapidly within the egg from which it can be extracted as a vaccine. The amount extracted is referred to as the yield.

According to the report the World Health Organisation is trying to produce samples that yield more antigen.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU